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INTRODUCTION
Chronic lymphocytic leukemia (CLL) (1) is an incurable malignancy that is characterized by the progressive accumulation of mature B cells in the peripheral blood, lymph nodes, bone marrow, spleen, and liver. CLL typically affects the elderly population, many of whom have preexisting conditions that restrict the use of the current standard treatment, which involves the combination of chemotherapeutic agents (fludarabine and cyclophosphamide) and an antibody (rituximab) (2, 3) . Therefore, combination therapy that targets distinct biological pathways in CLL pathogenesis represents a significant step outside of the conventional chemotherapybased approach. Accordingly, we recently identified carfilzomib, a Food and Drug Administration (FDA)-approved second-generation ubiquitin-proteasome pathway (UPP) inhibitor (4) , as a potent pharmacologic agent that causes cytotoxicity in CLL cells before or after treatment with ibrutinib (5-9), an irreversible inhibitor of Bruton's tyrosine kinase (10) .
The UPP, which has been validated clinically as a therapeutic target (11), regulates many vital cellular processes including cell cycle progression, transcriptional regulation, signal transduction, apoptosis, immune response, and elimination of damaged proteins. Formation of a K48-linked polyubiquitin chain is the first step in the UPP that permits recognition of a protein targeted for degradation by the proteasome (12) . The 26S proteasome is a proteolytic complex with caspases-like activity (beta 1 subunit), trypsin-like activity (beta 2 subunit), and chymotrypsin-like activity (beta 5 subunit) (13) . Carfilzomib (also known as PR-171) is a tetrapeptide epoxyketone-based analog of the natural compound epoxomicin, which selectively and irreversibly inhibits the chymotrypsin-like activity of the proteasome (14-16).
5 phase I clinical trials in multiple myeloma indicated that carfilzomib is a more robust inhibitor of the chymotrypsin-like activity than bortezomib (18, 19) . Moreover, in multiple myeloma in vivo and in vitro studies indicated that carfilzomib can circumvent bortezomib resistance since some bortezomib resistant patients (20) and bortezomib resistant cell lines (21) remain responsive to carfilzomib therapeutic effects. In CLL, earlier preclinical studies indicated that in vitro treatment of CLL cells with bortezomib resulted in significant cell death by apoptosis (22, 23) , however, in a phase II clinical trial conducted with bortezomib in fludarabine-refractory CLL patients, no patients achieved complete or partial responses. Though, some biological activity was observed (e.g. ≥50% decrease in absolute lymphocyte count, lymph nodes and spleen size was achieved in some of the patients) (24) . Subsequently, it was shown that CLL refractory effect to bortezomib was due to its boronate moiety interaction with plasma components (25) (26) (27) .
Nevertheless, the biological activities observed with bortezomib in this high-risk factors and severe treatment-resistant group of CLL patients indicated that proteasome inhibitors with better efficacy and safety profiles in combination with agents with different toxicity profiles are warranted.
Carfilzomib cytotoxic activity in CLL has been described previously by our group (10) and by another (25) ; however, the molecular mechanism by which carfilzomib triggers cell death in CLL has not been elucidated. Furthermore, in our investigation, a bimodal distribution of cytotoxicity was observed in response to carfilzomib treatment: limited or substantial cell death (10) .
Therefore, in the present report, we first evaluated the cytotoxic effect of carfilzomib in 30 CLL patient samples at five different concentrations. We then used these CLL patient samples and additional B-cell lines to further examine the intracellular pathways implicated in carfilzomibinduced cell death. Finally, we investigated the molecular differences that could potentially be responsible for the heterogenic cytotoxic response to carfilzomib between patients. Thus, the 6 carfilzomib and carfilzomib-based combination therapies who could participate in further clinical studies. Our investigation identified the proapoptotic transcription factor CCAAT/enhancerbinding protein (C/EBP) homology protein (CHOP) as a biomarker that could predict sensitivity to carfilzomib in CLL.
Research. 
RESULTS

Carfilzomib induces a heterogeneous cytotoxic response in CLL patient samples
The cytotoxic effect of carfilzomib was evaluated in PBMCs isolated from 30 CLL patients (Table 1) . Apoptosis assessed by annexin V/PI double positivity showed a concentrationdependent response effect after carfilzomib treatment for 16 h, with cytotoxic response variability between patient samples ( Figure 1A) . For instance, the cytotoxic median response was 11.6% (range: 0.3%-60%) and 27.5% (range: 5.1%-68.4%) with 50 and 100 nM carfilzomib ( Figure 1B) , respectively. Next, we investigated correlations between clinical and prognostic markers and the cytotoxic effect of carfilzomib. A strong association between IgVH unmutated status (unfavorable biological marker) and lower cytotoxic effect of carfilzomib was observed at both 50 nM (p=0.0157) and 100 nM (p=0.0070) ( Figure 1C) . Similar associations could not be made with other prognostic factors (data not shown).
Expression of proteins affected by carfilzomib in CLL patient samples
Due to its inhibition of the proteasome, carfilzomib treatment resulted in a concentrationdependent accumulation of polyubiquitinated proteins and the stabilization of short-lived proteins (e.g., β-catenin and p-IκBα) (30, 31) (Figure 1D ). We next evaluated carfilzomib treatment effect on levels of pro and antiapoptotic proteins in CLL samples (n=7) representing a wide range of cytotoxic profile. Bcl-xL, Bcl-2, cIAP1, cIAP2, p65, and Puma protein expression levels were not affected by carfilzomib treatment (Figure 1E) . At higher concentrations of carfilzomib, however, some of these proteins showed decreased expression, likely due to their cleavage by caspases; for example, the appearance of a 23-kDa cleaved form of Bcl-2, previously shown to be generated by caspase activation and blocked by a pan caspase inhibitor (32) , was observed ( Figure 1E) . In response to carfilzomib treatment, MCL-1 ( Figure 1D ) and Noxa ( Figure 1D-E exception of that in the CLL-871 sample that was highly sensitive to carfilzomib at higher concentrations, in which decrease of MCL-1 protein was likely due to its cleavage by caspases (33) .
Carfilzomib induces an endoplasmic reticulum stress response in CLL patient samples
Carfilzomib treatment activated the endoplasmic reticulum (ER) stress pathway, as indicated by increased protein expression of two transcription factors, activator of transcription 4 (ATF4) and CHOP (34) (Figure 1D) . Furthermore, both the intrinsic and extrinsic apoptosis pathways were activated by carfilzomib in a concentration-dependent manner as determined by the accumulation of the active forms of caspase 9 and caspase 8, respectively ( Figure 1E) .
Activation of the initiator caspases resulted in activation of the downstream executioner caspase 3 and accumulation of cleaved PARP and cleaved Bcl-2 ( Figure 1E-D) .
Carfilzomib induces a similar protein signature in MEC1 and MEC2 CLL cell lines
To dissect the molecular mechanism that triggers the cytotoxic response of carfilzomib, we chose to use the MEC1 and MEC2 CLL cell lines (35) . Carfilzomib induced a similar cytotoxic and molecular response in these cell lines. Carfilzomib treatment for 24 h was cytotoxic to MEC cell lines in a concentration-dependent manner (Figure 2A) . Molecular responses such as accumulation of polyubiquitinated proteins ( Figure 2B ) and stabilization of the short-lived protein β-catenin ( Figure 2C ) were comparable to those observed in primary CLL lymphocytes.
Changes in pro and antiapoptotic protein expression indicated a similar response to those in the CLL patient samples (Figure 2B-C) . The appearance of a 23-KDa, 55-kDa and 24-KDa cleaved form of Bcl-2, Hsp90 and MCL-1, respectively, previously shown to be generated by caspase activation and blocked by a pan caspase inhibitor (32, 33, 36) , were observed (Figure 2C-D) .
Moreover, carfilzomib treatment did not affect the expression of the proapoptotic proteins Bax and Bak (Figure 2C ).
Research. The unfolded protein response (UPR) is triggered when the ER function is disturbed (34) and consists of three signaling pathways controlled by transcription factors ATF4, ATF6, and Xbox binding protein 1 (XBP1s) (34) . ATF6 protein expression level did not change after carfilzomib treatment (Figure 2B) , and XBP1s protein was not affected in MEC1, but showed a slight increase in MEC2 ( Figure 2B) . Similar to what we observed in CLL patient samples, carfilzomib treatment triggered a comparable ER stress response, as noted by the increased protein level of ATF4 and CHOP ( Figure 2B) . ATF3 protein, which is also regulated by the ATF4 UPR arm (37) , was also increased by carfilzomib treatment (Figure 2B Furthermore, to determine whether there were differences in MCL-1, Bak, Noxa, and CHOP protein levels at baseline, and in MCL-1/Noxa and MCL-1/Bak ratios, we quantified the immunoblot band corresponding to these proteins in untreated samples for each patient ( Figure   6C ). Differences in MCL-1/Noxa (p=1.000) and MCL-1/Bak (p=0.9696) ratios were not significant between both sets of patients. Differences in protein expression at baseline between both sets of patients were significant only for CHOP (p=0.0488), with the set of patients with high cytotoxicity showing the highest level of CHOP protein ( Figure 6D) . These results identified the CHOP protein level as a biomarker to predict sensitivity to the cytotoxic effect of carfilzomib in CLL. 
DISCUSSION
CLL is the most common leukemia of the Western world and primarily affects the elderly population, who are often not healthy enough to undergo chemotherapy. Recently, we showed that carfilzomib, a selective and irreversible proteasome inhibitor, is a potent cytotoxic agent in CLL samples isolated from patients treated with ibrutinib, a well-tolerated, orally bioavailable Bruton's tyrosine kinase inhibitor (10) . While our present manuscript was under preparation a phase I trial conducted in a group of 19 patients with relapsed/refractory CLL showed modest activity of carfilzomib (43). In this study, the patient population was high risk with very unfavorable clinical and prognostic factors (i.e., 84% had a Rai stage between 3 and 4, 85%
were IgVH unmutated, 47% had del(17p), 21% had del(11q), 68% were refractory to fludarabine and 70% had complex karyotype), which probably contributed to the poor response observed with carfilzomib. For instance, a recent report indicated that complex karyotype and fludarabinerefractory disease showed poor outcome for CLL patients treated with ibrutinib-based regimens However, similar studies need to be conducted to establish any correlation between ER stress response and clinical outcome during carfilzomib therapy.
Noxa protein accumulation (but not Noxa mRNA) after carfilzomib treatment in CLL patient samples has been reported previously (10, 25) ; however, the biological significance of this 
observation has not been investigated. In our study, carfilzomib treatment resulted in accumulation of both the proapoptotic BH3-only protein Noxa and the antiapoptotic protein MCL-1. Accumulated Noxa and MCL-1 were polyubiquitinated and preferentially formed a complex, causing a shift in the balance between the proapoptotic executioner Bak and MCL-1.
Depletion of Noxa, Bak, and Bax proteins provided protection against carfilzomib's cytotoxic effect. Notably, in contrast to this study and to our previous report (10), Gupta et al. (25) observed no changes in markers associated with activation of the ER stress response.
Nonetheless, we showed that carfilzomib preferentially engaged the ATF4 branch of the UPR.
The unresolved ER stress response resulted in the accumulation of the transcription factor CHOP, and its depletion had a protective effect against carfilzomib-induced cell death. Taken together, our results confirm the importance of the ER stress pathway and specifically the induction of proapoptotic proteins CHOP and Noxa in the cytotoxic activity of carfilzomib.
We were the first to report that carfilzomib treatment in CLL patient samples resulted in the activation of both the intrinsic and extrinsic apoptotic pathways (10), which we confirmed in the present study. Bcl-2 family members play an important role in the engagement of the intrinsic apoptotic pathways (57) . Particularly, equilibrium between proapoptotic and antiapoptotic members is crucial to maintain the integrity of the outer membrane of the mitochondria and prevent the release of cytochrome c, a key component of the apoptosome complex responsible for the activation of the initiator caspase 9 (58). Our study indicated that carfilzomib treatment resulted in upregulation of a protein complex between the proapoptotic BH3-only protein Noxa and the antiapoptotic protein MCL-1, which probably contributed to the unleashing of Bak.
Consequently, depletion of Noxa, or depletion of Bax and Bak, the two executioners of mitochondrial outer membrane permeabilization, resulted in a protective effect against the carfilzomib cytotoxic effect. In this study, we showed interplay between Noxa, MCL-1, and Bak; however, because we used cells deficient in both Bak and Bax, we could not determine whether Bak is the preferred apoptotic executioner. Furthermore, higher cytotoxic concentrations of was recently reported in solid tumors (63) . Moreover, implication of the extrinsic pathway is also suggested by the fact that deficiency in Bax and Bak proteins did not confer complete protection against carfilzomib-induced cell death.
In conclusion, by using primary CLL lymphocytes as well as cell lines, we showed that the cytotoxic effect of carfilzomib induced a proapoptotic response that involved the Bcl-2 family members Noxa, MCL-1, Bax, and Bak as well as an unresolved ER stress response that resulted in upregulation of the proapoptotic transcription factor CHOP. Accordingly, carfilzomibinduced cytotoxic, apoptotic and ER stress responses were significantly affected in carfilzomib resistant cells. Importantly, we identified the CHOP protein level as an important determinant in the cytotoxic efficacy of carfilzomib in CLL. 
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